These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2258 related articles for article (PubMed ID: 25596560)

  • 1. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
    Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
    Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
    Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
    Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
    J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy.
    Han HS; Choi KY; Ko H; Jeon J; Saravanakumar G; Suh YD; Lee DS; Park JH
    J Control Release; 2015 Feb; 200():158-66. PubMed ID: 25550153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
    Ling L; Ismail M; Du Y; Yao C; Li X
    Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery.
    Yang C; Wang X; Yao X; Zhang Y; Wu W; Jiang X
    J Control Release; 2015 May; 205():206-17. PubMed ID: 25665867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
    Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
    J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
    Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
    Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
    Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
    J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular release of doxorubicin from core-crosslinked polypeptide micelles triggered by both pH and reduction conditions.
    Wu L; Zou Y; Deng C; Cheng R; Meng F; Zhong Z
    Biomaterials; 2013 Jul; 34(21):5262-72. PubMed ID: 23570719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
    Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
    Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery.
    Zou A; Chen Y; Huo M; Wang J; Zhang Y; Zhou J; Zhang Q
    J Pharm Sci; 2013 Jan; 102(1):126-35. PubMed ID: 23073894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
    Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
    J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin.
    Cho HJ; Yoon IS; Yoon HY; Koo H; Jin YJ; Ko SH; Shim JS; Kim K; Kwon IC; Kim DD
    Biomaterials; 2012 Feb; 33(4):1190-200. PubMed ID: 22074664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 113.